David Gordon
Head of Digital Health Investments @ Longliv Ventures
David Gordon is a Series C investor at Longliv Ventures focused on Medical and Health Care. David Gordon is the head of Digital Health Investments at Longliv Ventures.
- Total investments:
- 2
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries David Gordon invests in
Stages David Gordon invests in
Countries David Gordon invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Medical 1 (50%)
- Health Care 1 (50%)
- Medical Device 1 (50%)
- Computer Vision 1 (50%)
- Machine Learning 1 (50%)
Stage
- Series C 1 (50%)
- Series D 1 (50%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Sight Diagnostics is a blood diagnostic company that combines machine vision and AI to improve health through fast, convenient and accurate diagnostics. Developed over almost a decade of research, Sight’s technology combines the latest innovations in blood sample preparation, optics, chemistry, biology, physics and computer science.Sight’s firstproduct, Parasight*, has diagnosed malaria in close to 1 million tests across 24 countries. Sight OLO, Sight’s latest FDA 510(k) cleared blood analyzer, digitizes blood with only 2 drops of a finger prick or venous sample and provides lab-grade Complete Blood Count results in minutes. Sight has growing offices in the UK, the US and Israel, and commercial footprint on 5 continents.*Note: Parasight is not available for sale in the US and did not receive FDA clearance for use in the US. | $71M / Series D / Aug 05, 2020 | ||
| Sight Diagnostics is a blood diagnostic company that combines machine vision and AI to improve health through fast, convenient and accurate diagnostics. Developed over almost a decade of research, Sight’s technology combines the latest innovations in blood sample preparation, optics, chemistry, biology, physics and computer science.Sight’s firstproduct, Parasight*, has diagnosed malaria in close to 1 million tests across 24 countries. Sight OLO, Sight’s latest FDA 510(k) cleared blood analyzer, digitizes blood with only 2 drops of a finger prick or venous sample and provides lab-grade Complete Blood Count results in minutes. Sight has growing offices in the UK, the US and Israel, and commercial footprint on 5 continents.*Note: Parasight is not available for sale in the US and did not receive FDA clearance for use in the US. | $27.8M / Series C / Feb 14, 2019 |
Co-Investors
About Longliv Ventures
Targeting early stage companies with the intent uncover and nourish Consumer Digital Health solutions that will augment and eventually revolutionize the way people manage their health and wellness. Such solutions – that converge healthcare with the world of retail - could benefit from the Group’s global footprint, e.g. 14,500 retail stores in 24markets
Longliv Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
David Gordon
Head of Digital Health Investments
|
|||
|
Dan Eldar
Executive Director
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does David Gordon invest in?
David Gordon invests primarily in Medical, Health Care and Medical Device startups, most often at Series C and Series D stage. Most of the 2 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact David Gordon?
Public channels for David Gordon include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did David Gordon last invest?
The most recent investment recorded for David Gordon closed in Aug 2020. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
